Cryoport Toekomstige groei

Future criteriumcontroles 0/6

Cryoport zal naar verwachting groeien in winst en omzet met respectievelijk 51.9% en 7.5% per jaar. De winst per aandeel zal naar verwachting groeien met 54.2% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -10.5% zijn.

Belangrijke informatie

51.9%

Groei van de winst

54.2%

Groei van de winst per aandeel

Life Sciences winstgroei	18.3%
Inkomstengroei	7.5%
Toekomstig rendement op eigen vermogen	-10.5%
Dekking van analisten	Good
Laatst bijgewerkt	18 Nov 2024

Recente toekomstige groei-updates

Recent updates

Slammed 28% Cryoport, Inc. (NASDAQ:CYRX) Screens Well Here But There Might Be A Catch

Jun 25

Potential Upside For Cryoport, Inc. (NASDAQ:CYRX) Not Without Risk

Apr 15

Cryoport, Inc. (NASDAQ:CYRX) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Mar 15

Cryoport Tanks On Chilling Results And Bad Decisions

Mar 14

Is Cryoport (NASDAQ:CYRX) Using Debt In A Risky Way?

Mar 10

Fewer Investors Than Expected Jumping On Cryoport, Inc. (NASDAQ:CYRX)

Jan 15

Health Check: How Prudently Does Cryoport (NASDAQ:CYRX) Use Debt?

Oct 06

Downgrade: Here's How Analysts See Cryoport, Inc. (NASDAQ:CYRX) Performing In The Near Term

Jul 23

Cryoport, Inc.'s (NASDAQ:CYRX) Subdued P/S Might Signal An Opportunity

Jul 12

Is Cryoport (NASDAQ:CYRX) A Risky Investment?

Jun 13

Cryoport, Inc.'s (NASDAQ:CYRX) Intrinsic Value Is Potentially 96% Above Its Share Price

Mar 06

Cryoport, Inc. (NASDAQ:CYRX) Analysts Just Cut Their EPS Forecasts Substantially

Nov 07

Is Cryoport (NASDAQ:CYRX) Using Debt In A Risky Way?

Sep 23

Cryoport: A Rare Investing Opportunity

Sep 22

Cryoport enters into strategic relationship with Takeda's BioLife Plasma Services

Sep 08

Cryoport: Rapid Growth Is Great, But Shares Look Overpriced

Jul 30

Cryoport: To Resume Aggressive Growth

May 11

Cryoport: An Industry Leader Basking In Industry Tailwinds

Apr 15

Cryoport: Risky Investment With Upside Potential

Apr 01

Cryoport: More Growth Going Into New Year 2022

Dec 29

Is Cryoport, Inc. (NASDAQ:CYRX) Trading At A 49% Discount?

Dec 05

Winst- en omzetgroeiprognoses

NasdaqCM:CYRX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	266	-47	-18	10	7
12/31/2025	246	-51	-30	-5	9
12/31/2024	228	-88	-23	-3	10
9/30/2024	226	-166	-36	-8	N/A
6/30/2024	226	-181	-45	-11	N/A
3/31/2024	225	-121	-46	-7	N/A
12/31/2023	233	-108	-46	-1	N/A
9/30/2023	236	-55	-41	0	N/A
6/30/2023	241	-47	-32	3	N/A
3/31/2023	248	-38	-29	0	N/A
12/31/2022	237	-45	-26	-2	N/A
9/30/2022	233	-296	-27	-3	N/A
6/30/2022	230	-297	-23	5	N/A
3/31/2022	222	-293	-12	15	N/A
12/31/2021	223	-284	-17	8	N/A
9/30/2021	215	-76	-25	-4	N/A
6/30/2021	169	-78	-32	-18	N/A
3/31/2021	122	-77	-34	-22	N/A
12/31/2020	79	-75	-25	-15	N/A
9/30/2020	40	-22	-11	-4	N/A
6/30/2020	38	-23	-6	0	N/A
3/31/2020	37	-20	-5	0	N/A
12/31/2019	34	-18	-7	-1	N/A
9/30/2019	30	-20	-8	-2	N/A
6/30/2019	26	-9	-7	-2	N/A
3/31/2019	22	-9	-6	-2	N/A
12/31/2018	20	-10	-6	-3	N/A
9/30/2018	17	-10	-7	-4	N/A
6/30/2018	15	-9	N/A	-5	N/A
3/31/2018	13	-9	N/A	-4	N/A
12/31/2017	12	-8	N/A	-4	N/A
9/30/2017	11	-10	N/A	-3	N/A
6/30/2017	10	-10	N/A	-4	N/A
3/31/2017	9	-12	N/A	-5	N/A
12/31/2016	8	-13	N/A	-6	N/A
9/30/2016	7	-12	N/A	-6	N/A
6/30/2016	6	-12	N/A	-6	N/A
3/31/2016	6	-15	N/A	-6	N/A
12/31/2015	6	-16	N/A	-6	N/A
9/30/2015	5	-15	N/A	-5	N/A
6/30/2015	4	-16	N/A	-5	N/A
3/31/2015	4	-12	N/A	-4	N/A
12/31/2014	4	-10	N/A	-4	N/A
9/30/2014	3	-10	N/A	-4	N/A
6/30/2014	3	-21	N/A	-4	N/A
3/31/2014	3	-20	N/A	-4	N/A
12/31/2013	2	-20	N/A	-4	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat CYRX de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat CYRX de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat CYRX de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van CYRX ( 7.5% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 9% per jaar).

Hoge groei-inkomsten: De omzet van CYRX ( 7.5% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat CYRX binnen 3 jaar verliesgevend zal zijn.

Cryoport Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates upgraded to US$1.85 loss

Consensus EPS estimates fall by 44%

Price target decreased by 23% to US$12.75

Consensus EPS estimates fall by 14%

Cryoport, Inc. Reiterates Revenue Guidance for the Full Year 2024

Consensus EPS estimates fall by 26%

Recent updates

Chairman notifies of intention to sell stock

Consensus EPS estimates upgraded to US$1.85 loss

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Cryoport (NASDAQ:CYRX) A Risky Investment?

Consensus EPS estimates fall by 44%

The Market Lifts Cryoport, Inc. (NASDAQ:CYRX) Shares 36% But It Can Do More

Price target decreased by 23% to US$12.75

Second quarter 2024 earnings: EPS misses analyst expectations

Cryoport, Inc. (NasdaqCM:CYRX) announces an Equity Buyback for $200 million worth of its shares.

New major risk - Share price stability

Cryoport, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Health Check: How Prudently Does Cryoport (NASDAQ:CYRX) Use Debt?

Slammed 28% Cryoport, Inc. (NASDAQ:CYRX) Screens Well Here But There Might Be A Catch

Independent Lead Director recently sold US$109k worth of stock

Consensus EPS estimates fall by 14%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Cryoport, Inc. Reiterates Revenue Guidance for the Full Year 2024

Cryoport, Inc. to Report Q1, 2024 Results on May 07, 2024

Potential Upside For Cryoport, Inc. (NASDAQ:CYRX) Not Without Risk

Cryoport, Inc., Annual General Meeting, May 17, 2024

Insufficient new directors

Consensus EPS estimates fall by 26%

Chairman notifies of intention to sell stock

Cryoport, Inc. (NASDAQ:CYRX) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Cryoport Tanks On Chilling Results And Bad Decisions

Cryoport, Inc. Announces Goodwill Impairment for the Quarter Ended December 31, 2023

Is Cryoport (NASDAQ:CYRX) Using Debt In A Risky Way?

Cryoport, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Cryoport, Inc. Announces Transition of Edward Zecchini from the Board of Directors to Sr. Vice President - Chief Digital & Technology Officer

Fewer Investors Than Expected Jumping On Cryoport, Inc. (NASDAQ:CYRX)

Cryoport, Inc. (NasdaqCM:CYRX) acquired Bluebird Express LLC.

New minor risk - Share price stability

Cryoport, Inc. Provides Revenue Guidance for the Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Cryoport, Inc. (NasdaqCM:CYRX) acquired Tec4Med Lifescience GmbH.

Cryoport, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Health Check: How Prudently Does Cryoport (NASDAQ:CYRX) Use Debt?

Chairman notifies of intention to sell stock

Consensus EPS estimates fall by 35%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS misses analyst expectations

Cryoport, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Downgrade: Here's How Analysts See Cryoport, Inc. (NASDAQ:CYRX) Performing In The Near Term

Consensus EPS estimates fall by 19%

Price target decreased by 17% to US$25.75

Cryoport, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2023

Cryoport, Inc.'s (NASDAQ:CYRX) Subdued P/S Might Signal An Opportunity

Is Cryoport (NASDAQ:CYRX) A Risky Investment?

Independent Lead Director recently sold US$155k worth of stock

Consensus EPS estimates upgraded to US$0.66 loss

First quarter 2023 earnings: EPS exceeds analyst expectations

Cryoport, Inc. Provides Revenue Guidance for the Year 2023

Chairman recently sold US$54k worth of stock

Cryoport, Inc.'s (NASDAQ:CYRX) Intrinsic Value Is Potentially 96% Above Its Share Price

Consensus EPS estimates fall by 54%, revenue upgraded

Full year 2022 earnings: EPS misses analyst expectations

No longer forecast to breakeven

Cryoport, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Forecast to breakeven in 2025

Independent Lead Director recently sold US$142k worth of stock

Consensus EPS estimates fall by 12%

Consensus EPS estimates fall by 10%

Cryoport, Inc. (NASDAQ:CYRX) Analysts Just Cut Their EPS Forecasts Substantially

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$46.11

Cryoport, Inc. Revises Revenue Guidance for the Year 2022

Cryoport, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Is Cryoport (NASDAQ:CYRX) Using Debt In A Risky Way?

Cryoport: A Rare Investing Opportunity